Fresenius Medical Care skizziert Wachstum Von Investing.com

Fresenius Medical Care (NYSE: FMS), a message about dialysis service leistungen and products, reports in the telephone conference about the written quarters 2024 am (specific date) of a solid operative and financial Leistung. CEO Helen Giza explored her first positive, lying behavior on a comparable basis in the US and an international Anstieg of 3%.

Trotz erhöhter Sterblichkeitsraten und Auswirkungen von Hurrikans erzielte Fresenius an organic Umsatzwachstum von 2% and erhte seine Prognosis for the Betriebsergebnis at 16%-18% for the Gesamtjahr.

White Recognition

– Fresenius Medical Care reports an organic health insurance of 2% and a health insurance of 10%.

– The Unternehmen have gone from 10%-14% to Margenziel in 2025 with an active Margin of 9.8%.

– The Einsparungen from the FME25 program will be carried out in the future before 2024 and believe in the third quarter of 2024 for an amount of 173 million euros.

– Fresenius bereitet ich de US-Markteinführung seiner HDF-fähigen 5008X-Maschine bis Ende 2025 voor een konzentriert sich on Optimierung der Lieferkette.

– The world has put an end to the disease of substance neutrality during the celebration of 2040, where the strong Stromabnahmeverträge (vPPAs) have become very negative.

– The personal situation has had a major impact and the external parties have made a selective selection of an excellent performance clinic in more ways.

Unternehmensausblick

– Fresenius bestätigt seinen Umsatzwachstumsausblick für 2024.

– The Erwartung for the Wachstum of the Betriebsergebnisses would be 16%-18% of the Gesamtjahr-angehoben.

– A number of detailed strategies were discussed at Capital Markets Day on June 17, 2025 in London.

Bearish highs

– The basic provision is negative on the bet with 20 million to 40 million euros out.

– Herausforderungen wie höhte Sterblichkeitsraten and Hurrikan-Auswirkungen besthen furtherhin.

– vPPAs have written a negative flow of 24 million euros on the expense in the quarter.

Bullish highs

– Positive effects on the items of Humacyte’s new business and the optimization of the Legacy portfolios.

– The US-Umsatz has a higher processing volume of 1%.

– The international segment achieved a turnover of 4%.

Paintings

– Care delivery is carried out during the quarter with a minimum impact of 2%, with a significant impact on delivery.

Highlights of the Frage-und-Antwort-Runde

– CEO Helen Giza spoke about the expansion of the Hurrikans on the Betrieb and deutete on a short distance.

– The excessive exposure is high and the Wachstumserwartungen, after normalization, have disappeared.

– The environment is clear, a waiting period of 2-3% is acceptable, with regard to improvements in the quality of life and the patients.

Fresenius Medical Care has considered various adjustments in this quarter, there are high sterblichkeitsraten and the Auswirkungen of Hurrikans, konnte aber the Kontinuität der Dialysedienstleistungen aufrechterhalten and Wachstum erzielen. The basis of an operational and strategic initiative with the FME25 program is that positive financing can take place.

When the Fresenius comes up with new product innovations and strengthens its long-term commitment, the uninteresting effect will be so clear that the activated renewal orders will be appreciated and long-term waits will be achieved.

InvestingPro Acknowledgment

The solid Leistung van Fresenius Medical Care im drited Quartal 2024 reflects itself in more Schlüsselkennzahlen von InvestingPro wider. The KGV (terminated) of the Unternehmens of 14.52 for the last month of the third quarter of 2024 has received a relatively attractive rating, uninterested when the Wachstumsaussichten of the Unternehmens berücksichtigt. Because the InvestingPro tip is encouraged, FMS is “a new KGV in the sale of an honest company that trades”.

The value of the US dollar is 21.42 million US dollars, with a gross margin of 25.13% in the third quarter of 2024. If the war has gone through a negative war at -1.15%, the context dies of the telephone conferences from the high expectations and the hurricane expansion plans that are being adopted.

Anyway, the Fresenius Medical Care has paid dividends for 27 years in the following right stops, who have an InvestingPro-Tipp review. When the financial stability of the subdivisions and their commitment to the implementation of the agreement was demonstrated, the reassignments of several quarters under brands were adopted.

Due to the cooperation with the operational efficiency, while the Einsparungen of the FME25 programs are invested, it reflects in the seine operation 8.21% of the profit that widens the month to Q3 2024. This Kennzahl for

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.